Invitrogen™ IL-10 Monoclonal Antibody (JES3-9D7), eBioscience™, Invitrogen™

Description

Description: The JES3-9D7 monoclonal antibody reacts with human interleukin-10 (IL-10). Applications Reported: The JES3-9D7 antibody has been reported for use in capture of human IL-10 by ELISA, intracellular flow cytometric analysis, and for neutralizing IL-10 bioactivity. (Use Functional Grade purified for functional studies cat. 16-7108). Applications Tested: The JES3-9D7 antibody has been tested as the capture antibody in a sandwich ELISA for analysis of human Interleukin-10 (IL-10) in combination with the biotin JES3-12G8 (13-7109) antibody for detection and recombinant human IL-10 (14-8109) as the standard. A suitable range of concentrations of this antibody for ELISA capture is 1-4 μg/mL. A standard curve consisting of doubling dilutions of the recombinant standard over the range of 1000 pg/mL - 8 pg/mL should be included in each ELISA plate. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

IL-10 encodes a protein that acts as a cytokine and is primarily produced by monocytes, with some production by lymphocytes. This cytokine has various effects on immunoregulation and inflammation, including down-regulating the expression of Th1 cytokines, MHC class II Ags, and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. Additionally, IL-10 can block NF-kappa B activity and is involved in the regulation of the JAK-STAT signaling pathway. Knockout studies in mice have suggested that this cytokine is an essential immunoregulator in the intestinal tract. Mutations in this gene have been associated with an increased susceptibility to HIV-1 infection and rheumatoid arthritis. Diseases associated with IL10 include Graft-Versus-Host Disease and Human Immunodeficiency Virus Type 1.